Viatris Inc, the US healthcare company formerly known as Mylan Laboratories, aims to add $1 billion by 2028 as global sales after its recent acquisitions in ophthalmology (eye care).
In India, the company acquired the ophthalmology business of Taparia family-backed Famy Life Sciences for $300 million (around Rs 2500 crore). Viatris will develop a handful of under-development products under phase 3 clinical trials.
These products are in the areas of dry eye disease, Blepharitis (inflammation of the eyelids), Presbyopia (gradual loss of eyes' ability to focus on nearby objects), Viatris said in an investor presentation.
Viatris will acquire Oyster Point